What This Means
This research suggests that for patients with acute coronary syndrome (ACS) who receive a stent procedure (PCI), stopping dual antiplatelet therapy (taking two blood-thinning medications together) after one month or less—rather than continuing for the standard 12 months—does not significantly raise the risk of heart attacks, strokes, or death overall. More importantly, this shorter approach cut the risk of serious bleeding roughly in half. When combining both the bleeding benefits and the ischemic risks, patients on the shorter regimen had better overall outcomes. However, not all patients appear to benefit equally: people who had a complete heart attack (STEMI) showed a signal of higher cardiovascular event risk, while those with less severe forms of ACS (NSTE-ACS) did not.
This research also suggests that how the short therapy is implemented matters greatly. Stopping both medications within one week, or switching to weaker single-drug therapy (aspirin or clopidogrel alone), appeared to raise the risk of heart events. By contrast, continuing two medications for at least two weeks before transitioning to a stronger single agent (ticagrelor or prasugrel) did not increase cardiovascular risk. Additionally, patients of East Asian ethnicity experienced a much greater reduction in bleeding compared to non-East Asian patients, pointing to potentially important biological or clinical differences between populations.
Overall, this study suggests that a carefully chosen short course of dual antiplatelet therapy may be a reasonable strategy for many ACS patients, particularly those at higher bleeding risk or of East Asian ethnicity, but that the specific drugs used, duration, and patient type all matter for whether the approach is safe and beneficial. These findings may help guide more individualized treatment decisions for patients after coronary stent procedures.